APOE and Alzheimer disease: In our model evaluations, we performed rigorous validation at the phenotype level using diagnoses and medications that serve as proxies for AD and at the genotype level by comparing the polygenic risk scores (PRSs) and Apolipoprotein E (APOE) ε4 allele count for the predictions of a holdout set.